Brian J. Malkin Additional Publications

| |

Überblick


Given his particular experiences, Brian Malkin frequently is asked to write on numerous FDA- and intellectual-property-law issues, including clinical trials and new product development for complex and challenging products, such as biotechnology products, orphan drugs, generic drugs, 505(b)(2) new drug applications, patent-term restoration under the Hatch-Waxman Act, biosimilar products, tobacco products, patent-term adjustment, risk management and due diligence. View Brian’s pre-McDermott articles below.